Enovis Earnings Call Highlights Recon Strength, Caution

Enovis Corporation ((ENOV)) has held its Q1 earnings call. Read on for the main highlights of the call.

Enovis Corporation’s latest earnings call painted a broadly upbeat picture, with strong execution in its Recon franchise and clear momentum in high‑growth extremities, supported by new technologies like Arvis and Nebula. Management acknowledged headwinds from tariffs, international volatility, and an SEC‑driven metrics change, yet emphasized margin expansion, EPS growth, and improving cash flow as evidence of resilient fundamentals.

Top-Line Growth Holds Despite Calendar and Mix Effects

Enovis reported first‑quarter sales of $589 million, up 5% year over year, with organic revenue growing 3% and days‑adjusted organic growth reaching 6% once fewer selling days are accounted for. Foreign exchange added about 420 basis points to growth while the divestiture of Dr. Comfort shaved roughly 210 basis points off, highlighting how portfolio shifts and currency shaped headline results.

Recon Segment Leads with Robust Extremities and Hip Momentum

The Recon segment again proved to be the engine of the business, delivering 8% days‑adjusted growth and 6% organic growth overall. U.S. Recon climbed 8% organically, powered by a 10% surge in extremities and 6% growth in hips and knees, while international Recon grew 3% with double‑digit extremities gains and Nebula systems helping unlock new hip opportunities.

P&R Shows Pockets of Strength Amid Ongoing Reshaping

Prevention & Recovery posted a modest 1% organic increase, translating to about 3% growth after normalizing for selling days, underscoring a more mixed backdrop than Recon. Within P&R, global bracing grew around 3% on a days‑adjusted basis and bone stimulation delivered high single‑digit growth, suggesting select categories are gaining traction even as the portfolio is pruned and repositioned.

Margin Expansion and EPS Growth Underscore Operating Leverage

Adjusted gross margin reached 62%, with roughly 40 basis points of underlying improvement driven by favorable mix, productivity, and integration synergies. Adjusted EBITDA margin stood at 17.6%, slipping about 10 basis points on an underlying basis due mainly to stepped‑up R&D and expense phasing, yet adjusted EPS rose to $0.89, implying around 10% underlying growth with a 21% tax rate and flat $9 million interest expense.

Cash Flow Improves as Capital Remains Focused on Recon

Free cash flow improved by approximately $16 million year over year in the quarter, reinforcing management’s confidence in achieving stronger conversion over the coming years. Capital spending is being channeled heavily into Recon instrumentation, which accounts for about half of CapEx, and total CapEx is expected to remain roughly in line with last year as a percentage of sales, signaling disciplined but growth‑oriented investment.

Innovation and ASC Penetration Fuel Future Share Gains

The company highlighted a robust innovation pipeline, notably the Arvis platform showcased at AAOS and early shoulder cases, including the first outside‑U.S. shoulder in South Africa, alongside Nebula instrument sets that are aiding conversions. Ambulatory surgery center penetration is rising, with more than a quarter of primary knees now done in ASCs and shoulder procedures in the teens, and Arvis’s flexible purchase, lease, or per‑case model aims to accelerate ASC adoption and competitive wins.

Tariffs Add Cost Pressure, Particularly in P&R

Management disclosed roughly $4 million of tariffs incurred in the quarter, with the burden falling largely on the P&R segment and contributing to its softer profit profile. The company is absorbing and mitigating part of these costs but assumes no refunds in its outlook and expects tariff payments to persist at current levels, effectively baking this drag into its earnings framework.

International Volatility and Middle East Exposure Create Noise

International performance was described as choppy, with early‑year disruptions such as doctor and nurse strikes and other local issues suppressing volumes in certain markets. Enovis also flagged revenue exposure in the Middle East of about $1–2 million per month, and while management believes this can be absorbed within existing guidance, it acknowledged the region as a source of near‑term uncertainty.

Selling Days and Seasonality Mask Underlying Momentum

The quarter was pressured by fewer selling days, which management estimated created roughly a 240 basis point headwind to reported growth, artificially muting the underlying demand trends. Those lost days are expected to partially return, with one day added back in the second quarter and another in the fourth, and the team reminded investors that cash flow is seasonally softer in the first quarter due to bonus payments and major industry events.

SEC-Driven Change Narrows Adjusted EBITDA Flexibility

Following discussions with regulators, Enovis revised its adjusted EBITDA definition starting in the quarter, no longer excluding inventory step‑up charges linked to acquisitions such as Lima. The shift, which aligns with SEC staff conclusions, reduces comparability to prior non‑GAAP figures but brings the company’s reporting closer to regulatory expectations and leaves underlying economic performance unchanged.

P&R and Spending Weigh on Segment Margins

While topline trends were encouraging in Recon, P&R’s modest 1% organic growth and disproportionate tariff exposure constrained overall profit progression, contributing to the small underlying dip in EBITDA margin. At the same time, higher R&D investments, integration spending, and about $53 million of quarterly outflows for property, plant, equipment, and intangibles lifted investment cash outflows, signaling a deliberate push to fund innovation and integration.

Guidance Discipline Reflects Macro Caution Despite Momentum

Management reaffirmed its 2026 framework, expecting revenue to be balanced between the first and second halves of the year and targeting free cash flow conversion above 25%, even while absorbing Middle East disruptions and supply‑chain inflation. The team cited ongoing macro and geopolitical uncertainty as reasons not to raise guidance despite solid early‑year Recon traction, underscoring a preference for prudence over optimism as they navigate tariffs, FX swings, and volatile international conditions.

Enovis’s earnings call delivered a constructive message: strong Recon growth, improving margins, and better free cash flow are building a solid foundation, while innovation platforms like Arvis and Nebula deepen its competitive moat. Risks from tariffs, international volatility, and modest P&R performance remain, but the company’s steady guidance and disciplined capital allocation suggest a balanced risk‑reward profile for investors tracking its long‑term health‑care growth story.